Spinouts working on ketamine-based therapeutics, regenerative medicines for dogs and better sleep are among those that caught our eye this month.
These are the spinouts that caught our eye over the past month. Here's why they should be on your radar, too.
Public market challenges are leading corporates to reconsider their strategies, with some spinning off their venturing divisions.
Europe is starting to catch up to the US in terms of investor interest in spinouts, just in time for anticipated regulatory changes in Italy that will increase tech transfer activity.
It was fascinating to see Tencent lead the $23m series D round for Academia.edu, a US-based platform for academics to share research papers.
Despite being the first year spent entirely during the pandemic, 2021 underlined the strengths of the ecosystem with spinouts raising nearly $39.2bn.
Cambridge Innovation Capital is expected to blast past its goal for its second fund currently being raised.
We are but at the beginning of fundamental change brought about by university research commercialisation.
Editor-in-chief James Mawson ponders what lies ahead for corporate venture capital.
University research and spinouts could be caught in UK's push on national security.
The corporate venturing industry is pushing towards a 50:50 split in senior investor roles.
A decade's focus on digitalisation leaves physical assets vulnerable.
In the first part of our look at 2021's corporate venturing trends, we examine the growth in funding, IPOs and SPAC mergers, a big year for M&A and the emergence of CVC in new sectors.
GEC Healthcare Q1 2021 forward by Rob Coppedge, chief executive, Echo Health Ventures, and Bill Taranto, and president, Merck Global Health Innovation Fund